85 related articles for article (PubMed ID: 17198084)
1. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
Lopes de Menezes DE; Denis-Mize K; Tang Y; Ye H; Kunich JC; Garrett EN; Peng J; Cousens LS; Gelb AB; Heise C; Wilson SE; Jallal B; Aukerman SL
J Immunother; 2007 Jan; 30(1):64-74. PubMed ID: 17198084
[TBL] [Abstract][Full Text] [Related]
2. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.
Cardarelli PM; Quinn M; Buckman D; Fang Y; Colcher D; King DJ; Bebbington C; Yarranton G
Cancer Immunol Immunother; 2002 Mar; 51(1):15-24. PubMed ID: 11845256
[TBL] [Abstract][Full Text] [Related]
3. Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin.
Srivastava S; Pelloso D; Feng H; Voiles L; Lewis D; Haskova Z; Whitacre M; Trulli S; Chen YJ; Toso J; Jonak ZL; Chang HC; Robertson MJ
Cancer Immunol Immunother; 2013 Jun; 62(6):1073-82. PubMed ID: 23604103
[TBL] [Abstract][Full Text] [Related]
4. CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab.
Dijoseph JF; Dougher MM; Armellino DC; Kalyandrug L; Kunz A; Boghaert ER; Hamann PR; Damle NK
Cancer Immunol Immunother; 2007 Jul; 56(7):1107-17. PubMed ID: 17160682
[TBL] [Abstract][Full Text] [Related]
5. Chimeric B72.3 mouse/human (IgG1) antibody directs the lysis of tumor cells by lymphokine-activated killer cells.
Primus FJ; Pendurthi TK; Hutzell P; Kashmiri S; Slavin DC; Callahan R; Schlom J
Cancer Immunol Immunother; 1990; 31(6):349-57. PubMed ID: 2386980
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of the antibody-dependent cellular cytotoxicity of human peripheral blood lymphocytes with interleukin-2 and interferon alpha.
Vuist WM; Visseren MJ; Otsen M; Bos K; Vyth-Dreese FA; Figdor CG; Melief CJ; Hekman A
Cancer Immunol Immunother; 1993; 36(3):163-70. PubMed ID: 8439976
[TBL] [Abstract][Full Text] [Related]
7. Human recombinant interleukin-6 enhances antibody-dependent cellular cytotoxicity of human tumor cells mediated by human peripheral blood mononuclear cells.
Tsang KY; Finch MD; Primus FJ; Schlom J
Cancer Immunol Immunother; 1991; 34(1):9-16. PubMed ID: 1836975
[TBL] [Abstract][Full Text] [Related]
8. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism.
Hatjiharissi E; Xu L; Santos DD; Hunter ZR; Ciccarelli BT; Verselis S; Modica M; Cao Y; Manning RJ; Leleu X; Dimmock EA; Kortsaris A; Mitsiades C; Anderson KC; Fox EA; Treon SP
Blood; 2007 Oct; 110(7):2561-4. PubMed ID: 17475906
[TBL] [Abstract][Full Text] [Related]
9. Enhanced antitumor activity of a combination treatment with a mouse/human chimeric anti-MK-1 antibody and lymphokine-activated killer cells in vitro and in a severe combined immunodeficient mouse xenograft model.
Yamamoto T; Arakawa F; Nakamura K; Senba T; Tomita Y; Ikeda S; Kuroki M
Cancer Immunol Immunother; 1999 Jul; 48(4):165-71. PubMed ID: 10431685
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of interleukin-2 and mismatched double-stranded RNA, individually and in combination, against a human malignant melanoma xenograft.
Hubbell HR; Vargas HE; Tsujimoto KL; Gibson GD; Pequignot EC; Bigler RD; Carter WA; Strayer DR
Cancer Immunol Immunother; 1992; 35(3):151-7. PubMed ID: 1638550
[TBL] [Abstract][Full Text] [Related]
11. A strategy for evaluating lymphokine activation and novel monoclonal antibodies in antibody-dependent cell-mediated cytotoxicity and effector cell retargeting assays.
Junghans RP
Cancer Immunol Immunother; 1990; 31(4):207-12. PubMed ID: 2379218
[TBL] [Abstract][Full Text] [Related]
12. The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation.
Nakamura A; Grossman S; Song K; Xega K; Zhang Y; Cvet D; Berger A; Shapiro G; Huszar D
Blood; 2022 May; 139(18):2770-2781. PubMed ID: 35226739
[TBL] [Abstract][Full Text] [Related]
13. Combination strategies to enhance antitumor ADCC.
Kohrt HE; Houot R; Marabelle A; Cho HJ; Osman K; Goldstein M; Levy R; Brody J
Immunotherapy; 2012 May; 4(5):511-27. PubMed ID: 22642334
[TBL] [Abstract][Full Text] [Related]
14. Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer.
Patel S; Burga RA; Powell AB; Chorvinsky EA; Hoq N; McCormack SE; Van Pelt SN; Hanley PJ; Cruz CRY
Front Oncol; 2019; 9():196. PubMed ID: 31024832
[No Abstract] [Full Text] [Related]
15. NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy.
Wang W; Erbe AK; Hank JA; Morris ZS; Sondel PM
Front Immunol; 2015; 6():368. PubMed ID: 26284063
[TBL] [Abstract][Full Text] [Related]
16. NK cells in therapy of cancer.
Bachanova V; Miller JS
Crit Rev Oncog; 2014; 19(1-2):133-41. PubMed ID: 24941379
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-21 enhances rituximab activity in a cynomolgus monkey model of B cell depletion and in mouse B cell lymphoma models.
Krejsa CM; Holly RD; Heipel M; Bannink KM; Johnson R; Roque R; Heffernan J; Hill J; Chin L; Wagener F; Shiota F; Henderson K; Sivakumar PV; Ren HP; Barahmand-Pour F; Foster D; Clegg C; Kindsvogel W; Ponce R; Hughes SD; Waggie K
PLoS One; 2013; 8(6):e67256. PubMed ID: 23825648
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma.
Kurai J; Chikumi H; Hashimoto K; Takata M; Sako T; Yamaguchi K; Kinoshita N; Watanabe M; Touge H; Makino H; Igishi T; Hamada H; Yano S; Shimizu E
Int J Oncol; 2012 Nov; 41(5):1610-8. PubMed ID: 22922885
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation.
Ballesteros-Tato A; León B; Graf BA; Moquin A; Adams PS; Lund FE; Randall TD
Immunity; 2012 May; 36(5):847-56. PubMed ID: 22464171
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies for the treatment of cancer.
Shuptrine CW; Surana R; Weiner LM
Semin Cancer Biol; 2012 Feb; 22(1):3-13. PubMed ID: 22245472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
